Oxford Immunotec Global PLC and Qiagen NV have settled patent infringement litigation surrounding Qiagen's QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus tests for tuberculosis. Under the settlement, Oxford received a payment of $27.5mm and granted Qiagen a royalty-free, non-exclusive license extending to current and future customers of the products. Qiagen gained the QuantiFERON in vitro diagnostic technology through its $355mm acquisition of Cellectis in 2011. The platform can provide information on the activity of the cell-mediated function of the immune system from whole blood samples. (Dec.)
Akers Biosciences Inc. (rapid in vitro point-of-care screening and testing products) netted $6.4mm through a follow-on public offering of 21.5mm Class A units, including the overallotment, at $0.15 per unit (each Class A unit consists of one share of common stock and one warrant to purchase an additional common share) and 3.675k Class B Units (each Class B unit consists of one share of Series B convertible preferred stock (convertible into 24.5k common shares) and one warrant comparable to the Class A units) at $1k per unit
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?